Emergent Biosolutions

Yahoo Finance • 3 months ago

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Emergent BioSolutions $185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secure... Full story

Yahoo Finance • 4 months ago

Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa

Emergent BioSolutions Active engagement with the World Health Organization, U.S. government and other global health leaders on critical efforts to prevent mpox disease transmission 50,000 doses of ACAM2000®, (Smallpox (Vaccinia) Vaccine,... Full story

Yahoo Finance • 6 months ago

Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million

Emergent BioSolutions GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an... Full story

Yahoo Finance • 8 months ago

Emergent BioSolutions Reports First Quarter 2024 Financial Results

Emergent BioSolutions First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance range First Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 million Updates FY 2024 guidance GAITHERSBURG, Md., May... Full story

Yahoo Finance • 11 months ago

Emergent extends shelf life of opioid overdose reversal drug Narcan

Jan 17 (Reuters) - Emergent BioSolutions has extended shelf life of Narcan, its over-the-counter nasal spray to reverse opioid overdose, to four years from three, the U.S. health regulator said on Wednesday. The extension applies to the p... Full story

Yahoo Finance • 12 months ago

Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense

Emergent BioSolutions GAITHERSBURG, Md., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum va... Full story

Yahoo Finance • last year

Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and... Full story

Yahoo Finance • last year

Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

GAITHERSBURG, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 80... Full story

Yahoo Finance • last year

Emergent BioSolutions Reports Third Quarter 2023 Financial Results

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of  $(266)M and Adjusted EBITDA(2) of $20MUpdates FY 2023 guidance GAITHERSBURG, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Emergent B... Full story

Yahoo Finance • last year

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023

GAITHERSBURG, Md., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023... Full story

Yahoo Finance • last year

Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring... Full story

Yahoo Finance • last year

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

Emergent has officially shipped its over the counter, original prescription strength NARCAN® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy and grocery stores, as well as online retailers NARCAN® Nasal Spray will be the first... Full story

Yahoo Finance • 2 years ago

Why Emergent BioSolutions Stock Dived by 9% Today

Contract healthcare manufacturing company Emergent BioSolutions (NYSE: EBS) was looking a bit under the weather as far as its stock was concerned on Tuesday. Before market open, Emergent announced that CEO Robert Kramer informed its board... Full story

Yahoo Finance • 2 years ago

Emergent BioSolutions Announces CEO Transition

Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has inf... Full story

Yahoo Finance • 2 years ago

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At closing Emergent received $270 million, subj... Full story

Yahoo Finance • 2 years ago

Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions

COPENHAGEN, Denmark, May 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has completed its acquisition of the travel vaccine portfolio from Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”). With the closing of this t... Full story

Yahoo Finance • 2 years ago

Bavarian Nordic gennemfører købet af rejsevaccineportefølje fra Emergent BioSolutions

KØBENHAVN, Danmark, 15. maj 2023 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har afsluttet købet af rejsevaccineporteføljen fra Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”). Med afslutningen af denne transaktion... Full story

Yahoo Finance • 2 years ago

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 202... Full story

Yahoo Finance • 2 years ago

Q1 2023 Emergent BioSolutions Inc Earnings Call

Participants Paul Williams Richard S. Lindahl; Executive VP, CFO & Treasurer; Emergent BioSolutions Inc. Robert G. Burrows; VP of IR; Emergent BioSolutions Inc. Robert G. Kramer; CEO, President & Executive Director; Emergent BioSolutio... Full story

Yahoo Finance • 2 years ago

Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023

GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, rec... Full story